article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.

article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

article thumbnail

AstraZeneca partnership to pioneer UK’s first commercial biomethane supply

European Pharmaceutical Review

Once operational in early 2025, the partnership will reduce emissions by an estimated 20,000 tonnes CO 2 equivalent (CO 2 e). Alongside this move, AstraZeneca’s investment in major energy efficiencies in its operations, brings the total of its financial commitment to net zero, to £100 million.

article thumbnail

AbbVie Cork facility €60 million expansion

European Pharmaceutical Review

AbbVie , an international R&D biopharmaceutical enterprise has celebrated its 20th anniversary by investing in extensive renovations at its manufacturing site in Cork, Ireland. The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025.

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

Global Health Equity: Moving From Wish List to To-Do List

Eversana Intouch

Correspondingly, pharmaceutical manufacturers spend exponentially more on marketing healthcare, including more than $6 billion annually on direct-to-consumer advertising. In pharma, we get the chance to do that as we all fight for health equity in 2025 and beyond. If it were easy, wed all be doing it.